Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Ipca Laboratories Limited
IPCALAB | NSE
1,500.90
INR25.50
1.73%
IPCALAB | NSE
About Ipca Laboratories Limited
Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
Earnings date
31/03/2024
As of date
05/03/2026
Close
1,500.90
Open
1,475.40
High
1,507.00
Low
1,470.10
Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive anti-malarial diuretic DMARD and anthelmintic. The company provides generic and branded formulations in the therapeutic segments including allergy anti-neoplastic/cancer drugs anti-arthritic anti-epileptic anti-hypertensive cardiology dermatology diabetology gastroenterology haematology neurology ophthalmology rheumatology and urology as well as respiratory psychiatry probiotics orthopedics oral anti diabetes drug nutraceuticals NSAIDs neuropathic pain malaria infectious diseases immunosuppressant hepatoprotectives helminthics fever and emollients/protectives. It exports its products to approximately 100 countries worldwide. The company was incorporated in 1949 and is based in Mumbai India.
View LessIPCALAB | NSE
Risk
26.2
Sharpe
-0.03
Luna's Score
60/100
Recommendation
Hold
Luna says (IPCALAB | NSE)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
What's not Working
High Short-term Volatility
Midcap (2B - 10B USD)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
26.7%1 month
26.2%3 months
25.5%6 months
33.3%Returns
Fundamental Ratios
PE
72.46
Fwd. PE
-
Price to book
6.60
Debt to equity
0.23
Debt to assets
0.13
Ent. to EBITDA
30.35
Ent. to rev.
5.22
PEG
-
Other Fundamentals
EBITDA
13.42B
MarketCap
380.78B
MarketCap(USD)
4.14B
Div. yield
0.12
Op. margin
14.04
Erngs. growth
18.10
Rev. growth
31.80
Ret. on equity
7.67
Short ratio
-
Short perc.
-
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
111.20
Range1M
155.10
Range3M
220.90
Volumes: Market Activity
Rel. volume
0.33
Price X volume
92.70M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 30.35 | 24.85 | Expensive |
| Ent. to Revenue | 5.22 | 11.40 | Cheaper |
| PE Ratio | 72.46 | 51.36 | Expensive |
| Price to Book | 6.60 | 6.83 | Par |
| Dividend Yield | 0.12 | 0.52 | Poor |
| Std. Deviation (3M) | 25.52 | 42.17 | Lower Risk |
| Debt to Equity | 0.23 | 0.35 | Cheaper |
| Debt to Assets | 0.13 | 0.17 | Cheaper |
| Market Cap | 380.78B | 290.82B | Market Leader |
